Trial Profile
Randomized, Controlled, Parallel Group, Patient-Blinded, Single-Center Phase I Pilot Study to Assess Tolerability and Safety of Repeated s.c. Administration of a Single-Dose of AFFITOPE AD02 Applied With or Without Adjuvant to Patients With Mild-to-Moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2016
Price :
$35
*
At a glance
- Drugs Affitope AD02 (Primary) ; Aluminium hydroxide
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 18 Aug 2011 Status of the extension trial (NCT01357629) change from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Aug 2011 Status of the extension trial (NCT01357629) change from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Aug 2011 Status of the extension trial (NCT01357629) change from not yet recruiting to recruiting as reported by ClinicalTrials.gov.